In conclusion, the results from this breast cancer window-of-opportunity trial show statin-induced upregulation of LDLR in tumors with relatively high proliferation, as well as preserved intratumoral cholesterol levels, indicating that LDLR might play a role as a negative regulator in the statin-induced inhibition of breast cancer aggressiveness. This evidence concerns the gene LDLR and breast cancer.